Transarterial Chemoembolization Monotherapy and Radiofrequency Ablation or Ethanol Injection for HCC

Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world and the third most common cause of cancer-related death (Benson et al., 2009). Hepatic resection is still to get the possibility of cure for patients with HCC, but majority of patients diagnosed with HCC have loose surgery opportunity (Hsu et al., 2011). Radiofrequency ablation (RFA), percutaneous ethanol injection (PEI) and transarterial chemoembolization (TACE) have been considered to be effective treatment modalities for most patients of HCC (Golfieri et al., 2013; Xu et al., 2014a; 2014b; 2104c; 2014d; 2015a; 2015b; 2015c). Ultrasound guided RFA and PEI have been shown to be highly HCCs and multiple HCCs exceeding the Milan criteria (MC) have been widely treated by TACE, using chemotherapeutic agents such as cisplatin or epirubicin mixed with lipiodol and emboli cagents such as gelatin-spongeparticles. In this paper, we report results of our retrospective review conducted to evaluate the superiority, in terms of the survival rate and survival prolongation, of combined